University of British Columbia
Toward understanding 'what's in the bag' : investigating sources of blood product variability with a focus on donors with diabetes
Abstract
dc:descriptionBlood products are inherently variable biological therapies, with evidence of consistent inter-donor differences in characteristics and storage performance. As blood centres expand donor eligibility, data on newly accepted donor populations are needed to support evidence-based policy and advances in ‘precision’ transfusion medicine. This dissertation investigates donor-driven variability in platelet concentrates (PC) and red cell concentrates (RCC), initially focusing on newly eligible donors with diabetes and extending to multi-omics characterization of blood product variability. We present the first data on donors with type 1 diabetes (T1D), alongside converging analyses identifying type 2 diabetes (T2D)-associated effects on blood product quality. Canadian Blood Services quality control data showed small but statistically significant declines in PC and RCC quality at expiry from donors with T2D, with the largest effects in donors using both metformin and insulin. In vitro characterization confirmed that products from donors with well-controlled T1D were comparable to age/sex-matched controls, while products from donors with well-controlled T2D showed modest but consistent reductions in quality, particularly over storage. Multi-omics analyses suggested that broader cardiometabolic perturbations, rather than glycemic control alone, contribute to the T2D-associated phenotypes. In a larger prospective cohort of donors, multivariable modelling explored independent contributions of donor age, sex, body mass index (BMI), glycemic control, and diabetes type to in vitro measures of blood product quality. Together, these factors explained limited variance, but the modest independent effects of T2D on PC metabolic features and RCC hemolysis persisted after adjustment. BMI showed smaller independent associations with PC metabolic features, supporting a cardiometabolic continuum framework in which donor health may contribute additive effects on blood product quality. Taking a higher resolution approach to investigating variability, we also generated the largest washed-platelet proteomics dataset from PCs. This revealed novel proteomic associations with donor characteristics, and provided molecular insight into variability in PC function over storage and responses to emerging platelet-enhancing technologies. Collectively, although T2D-associated perturbations were detected, these data do not suggest clinically inferior outcomes for products from donors with diabetes, supporting their continued eligibility. More broadly, this work emphasizes the value of high-resolution multi-omics profiling in large cohorts to advance ‘precision’ transfusion medicine.
Degree
thesis:*- Name thesis:degree_name
- Doctor of Philosophy - PhD
- Level thesis:degree_level
- doctoral
- Discipline thesis:degree_discipline
- Pathology and Laboratory Medicine
- Grantor dc:publisher
- University of British Columbia
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Rowe, Elyn Marie
- Contributors dc:contributor
-
- Johnson, James D.
- Devine, Dana V.
Rights
dc:rights- Statement dc:rights
-
- Attribution-NonCommercial-NoDerivatives 4.0 International
- Language dc:language
- eng
Identifiers
dc:identifier.*- Handle dc:identifier
- http://hdl.handle.net/2429/94858